Related Experiment Videos
[Hepatitis C]
1Hospital de Clínicas, Universidade de São Paulo, São Paulo, SP. adna.strauss@hcnet.usp.br
Insights
Hepatitis C virus (HCV) infection affects 3% globally, with chronic cases often asymptomatic for years. Diagnosis involves anti-HCV testing and HCV-RNA confirmation, with liver biopsy for staging.
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Context:
- Hepatitis C virus (HCV) infection impacts approximately 3% of the global population.
- Risk factors include blood product transfusion, illicit drug use, and certain medical/cosmetic procedures.
- Chronic HCV infection develops in up to 85% of cases, often remaining asymptomatic for extended periods.
Purpose:
- To outline the diagnosis, staging, and treatment of Hepatitis C virus infection.
- To discuss the challenges and considerations in managing chronic HCV.
- To highlight the role of viral load and genotypes in predicting treatment response.
Summary:
- Diagnosis relies on anti-HCV antibody detection, confirmed by HCV-RNA identification.
- Liver biopsy is crucial for staging disease progression and assessing activity.
- Current treatments like interferon and ribavirin have limited efficacy and significant side effects, necessitating careful patient selection.
Impact:
- Understanding risk factors and diagnostic methods is key for early detection and intervention.
- Accurate staging and assessment of viral factors improve patient management strategies.
- Further research into more effective and safer HCV treatments is warranted.
Abstract:
It has been estimated that 3% of the world population is infected with the hepatitis C virus. Those who are blood product recipients or have been illicit drug users are at risk. Dental and medical procedures as well as tattooing and acupuncture are also risk factors. Chronic infection occurs in up to 85% of infected cases but they may remain without symptoms during years or even decades, and clinical presentation varies. Determination of anti-HCV in sera is a fairly sensitive tool for the diagnosis, and confirmation requires the identification of HCV-RNA. Staging of the liver disease as well as definition of its present activity can be graded by liver biopsy. The aim of treatment is to stop the progression of the hepatic disease by inhibiting viral replication. Due to the low therapeutic efficacy combined with important side-effects, the administration of interferon and ribavirin have specific indications and contraindications. Predictive factors of therapeutic response, particularly viral load and genotypes of HCV, are useful in the evaluation of patients.